Ascletis Reports Positive 28-Day U.S. Proof-of-Concept Results for Oral IL-17A Inhibitor ASC50
Ascletis reports positive 28-day U.S. proof-of-concept results for ASC50, a first-in-class oral small molecule IL-17A inhibitor for plaque psoriasis, potentially offering an oral alternative to injec…